Cosmo Pharmaceuticals N.V. (VIE:COPN)

Austria flag Austria · Delayed Price · Currency is EUR
92.50
-2.00 (-2.12%)
At close: Apr 2, 2026
Market Cap1.53B +67.6%
Revenue (ttm)104.17M -61.0%
Net Income-3.61M
EPS-0.23
Shares Outn/a
PE Ration/a
Forward PE942.60
Dividend2.10 (2.22%)
Ex-Dividend DateApr 24, 2026
Volumen/a
Average Volume22
Open93.00
Previous Close94.50
Day's Range92.50 - 93.50
52-Week Range44.80 - 141.00
Betan/a
RSI40.36
Earnings DateMar 9, 2026

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cor... [Read more]

Industry Pharmaceutical Preparations
Founded 1997
Employees 325
Stock Exchange Vienna Stock Exchange
Ticker Symbol COPN

Financial Performance

Financial Statements

News

Cosmo Pharmaceuticals NV (CMOPF) Full Year 2025 Earnings Call Highlights: Strong Financial ...

Cosmo Pharmaceuticals NV (CMOPF) Full Year 2025 Earnings Call Highlights: Strong Financial Performance and Strategic Growth Initiatives

26 days ago - GuruFocus

Full Year 2025 Cosmo Pharmaceuticals NV Earnings Call Transcript

Full Year 2025 Cosmo Pharmaceuticals NV Earnings Call Transcript

26 days ago - GuruFocus

Cosmo Pharmaceuticals (CMOPF) Reports Revenue Decline, Sets Positive 2026 Outlook

Cosmo Pharmaceuticals (CMOPF) Reports Revenue Decline, Sets Positive 2026 Outlook

4 weeks ago - GuruFocus

Cosmo Pharma Slips To Loss In FY25 On Weak Revenues; Stock Drops

(RTTNews) - Shares of Cosmo Pharmaceuticals N.V. (COPN.SW, CMOPF) were losing around 14 percent in the morning trading in Switzerland after the healthcare company reported a loss in its fiscal 2025, c...

4 weeks ago - Nasdaq